Locum Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Locum partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Locum Partners Today - Breaking & Trending Today

Barclays Trims Coherus BioSciences (NASDAQ:CHRS) Target Price to $8.00

Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its target price lowered by Barclays from $13.00 to $8.00 in a research note issued to investors on Tuesday, The Fly reports. A number of other equities research analysts have also issued reports on CHRS. StockNews.com started coverage on Coherus BioSciences in a research note on Thursday, May […] ....

Hong Kong , Dennism Lanfear , Alan Herman , Doug Farrar , Steve Glover , Coherus Biosciences , Hong Kong Ltd , Coherus Biosciences Company Profile , Coherus Biosciences Inc , Get Rating , Moderate Buy , Locum Partners , Kong Ltd , Pictet Asset Management , Asset Management , Redwood City , Coherus Biosciences Daily , Nasdaq Chrs , Lower Price Target , Barclays Plc ,

Coherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Up 22.5% in March

Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 12,050,000 shares, an increase of 22.5% from the February 28th total of 9,840,000 shares. Based on an average daily trading volume, of 1,260,000 shares, […] ....

Coherus Biosciences , Doug Farrar , Steve Glover , Dennism Lanfear , Alan Herman , Deutsche Bank , Aristotle Capital Boston , Alphacrest Capital Management , Cubist Systematic Strategies , Coherus Biosciences Inc , Get Rating , Locum Partners , Systematic Strategies , Crest Capital Management , Capital Boston , Redwood City , Coherus Biosciences Daily , Nasdaq Chrs ,

Coherus BioSciences (NASDAQ:CHRS) Upgraded to Buy at UBS Group

UBS Group upgraded shares of Coherus BioSciences (NASDAQ:CHRS – Get Rating) from a neutral rating to a buy rating in a report published on Tuesday morning, MarketBeat.com reports. The firm currently has $11.00 price objective on the biotechnology company’s stock. Several other equities research analysts have also commented on CHRS. HC Wainwright cut their price […] ....

Coherus Biosciences , Alan Herman , Dennism Lanfear , Doug Farrar , Steve Glover , Ubs Group , Cubist Systematic Strategies , Alphacrest Capital Management , Deutsche Bank , Coherus Biosciences Inc , Coherus Biosciences Company Profile , Aristotle Capital Boston , Get Rating , Moderate Buy , Locum Partners , Systematic Strategies , Crest Capital Management , Capital Boston , Redwood City , Coherus Biosciences Daily , Nasdaq Chrs , Ubs Group Ag ,

Femasys (NASDAQ:FEMY) Price Target Cut to $10.00

Femasys (NASDAQ:FEMY – Get Rating) had its target price reduced by stock analysts at Chardan Capital from $12.00 to $10.00 in a research report issued on Thursday, The Fly reports. Femasys Price Performance Shares of NASDAQ:FEMY traded down $0.05 during trading on Thursday, reaching $1.15. The company had a trading volume of 2,446 shares, compared […] ....

United States , Vanguard Group Inc , Clear Creek Financial Management , Hb Wealth Management , Femasys Inc , Femasys Company Profile , Get Rating , Chardan Capital , Creek Financial Management , Locum Partners , Vanguard Group , Femasys Daily , Nasdaq Femy , Lower Price Target ,